Yifan Pharmaceutical Co., Ltd. (002019.SZ)

Yifan Pharmaceutical Co., Ltd. (002019.SZ) — VMCI valuation read

Across 120 indicators, Yifan Pharmaceutical Co., Ltd. (002019.SZ) lands at VMCI 49/100. The Healthcare sector median is 50, so the 1-point below-median read is the active comparison. Pillar weighting on the score: Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%.

No material Form 4 disclosures landed on 002019.SZ in the past 30 days. Quiet insider tape removes one signal source; the active reads stay with the trailing-twelve-month financials and the next 10-Q.

**Investor frame.** On Value, 002019.SZ trades at 17.0x earnings, 6% below the Healthcare median of 18.0x; the EV/EBITDA delta of -2.0x reinforces that single line. On Quality, ROIC of 9.0% trails the Healthcare median (10.0%) by 1.0pp. On Risk, net debt to EBITDA of 1.8x is the rate-sensitivity line to watch for 002019.SZ on the trailing balance sheet.

002019.SZ fell 3.6% over the trailing 7 days, with a -17.4% read on a 30-day basis.